Semaglutide (5mg–30mg)

Semaglutide is a modified GLP-1 receptor agonist peptide with an extended half-life profile, supplied as a lyophilized powder for in-vitro laboratory research use. Purity specification: above 99% (HPLC-MS). Batch documentation is available on request. Provided as lyophilized powder for in-vitro research use only.

Laboratory programs frequently validate Semaglutide (5mg–30mg) with HPLC purity checks and mass confirmation before assay work begins.

Semaglutide (5mg–30mg) is commonly included in metabolic research panels investigating appetite-regulating pathways and energy homeostasis in laboratory models.

Studies evaluating Semaglutide (5mg–30mg) typically focus on receptor activation profiles and downstream metabolic signaling under controlled in-vitro conditions.

This product is available in 5mg and 10mg and 15mg. Each vial contains lyophilized peptide at the labeled quantity; wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only —not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with Semaglutide (5mg–30mg). Summaries are provided for orientation only and reflect the cited sources.

Once-Weekly Semaglutide in Adults with Overweight or Obesity^[1] —This landmark phase 3 trial (STEP 1) evaluated once-weekly semaglutide 2.4 mg in adults with overweight or obesity. The authors assessed body weight change compared with placebo over the treatment period, alongside secondary metabolic outcomes. They reported substantial weight loss with semaglutide, supporting its use as a treatment for overweight and obesity. (The New England journal of medicine 2021)

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes^[2] —This landmark cardiovascular outcomes trial (SUSTAIN-6) evaluated semaglutide in patients with type 2 diabetes at high cardiovascular risk. The authors assessed major adverse cardiovascular events and other safety outcomes during treatment. The results indicated a lower rate of cardiovascular events with semaglutide, informing its cardiovascular safety profile. (The New England journal of medicine 2016)

Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial^[3] —This randomised, double-blind, placebo-controlled phase 3b trial (STEP 12) evaluated once-weekly semaglutide 2.4 mg in Chinese adults with overweight or obesity. The authors assessed weight loss and safety outcomes in this population. The findings indicated that semaglutide was effective for weight management in Chinese adults, with a safety profile consistent with prior studies. (The lancet. Diabetes & endocrinology 2026)

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis^[4] —This prespecified secondary analysis of the SELECT trial examined the effect of semaglutide on the inflammatory biomarker high-sensitivity C-reactive protein in patients with established cardiovascular disease and overweight or obesity. The authors analyzed changes in this biomarker during treatment. The results indicated that semaglutide was associated with reductions in high-sensitivity CRP, suggesting potential anti-inflammatory effects. (Circulation 2026)

References

1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." The New England journal of medicine. 2021. pubmed.ncbi.nlm.nih.gov/33567185/
2. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." The New England journal of medicine. 2016. pubmed.ncbi.nlm.nih.gov/27633186/
3. Guo L, Bao X, Huang KC, Kolnes KJ, Laugesen C, Lu Y, Luo B, Yuan G, Kushner RF. "Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial." The lancet. Diabetes & endocrinology. 2026. pubmed.ncbi.nlm.nih.gov/42575111/
4. Plutzky J, Bogdański P, Colhoun HM, Dagdelen S, Deanfield JE, Emerson SS, Hovingh GK, Kahn SE, Ekström K, Latkovskis G, Lehrke M, Hardt-Lindberg S, Lingvay I, Nicholls SJ, Kalayci Oral T, Terns PP, Rasmussen S, Ridker PM, Ryan DH, Lincoff AM. "Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis." Circulation. 2026. pubmed.ncbi.nlm.nih.gov/42610271/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.